Small molecule · developed by Unicycive Therapeutics
Oxylanthanum carbonate is a phosphate binder studied for reducing hyperphosphatemia in patients with chronic kidney disease requiring chronic dialysis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06218290 | Phase 2 | Chronic Kidney Disease Requiring Chronic Dialysis | Completed | UNCY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Kidney Disease Requiring Chronic Dialysis
Updated Nov 1, 2026. Something wrong or missing? Report it on the UNCY page.
See UNCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
UNCY catalysts and pipeline →